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= 654) had statistically signiﬁcant lower PCS (−3.38, p < 0.001), MCS (−1.43, p < 
0.05), EQ-5D index (−0.024, p < 0.05), and VAS scores (−4.93, p < 0.001). Patients 
with diabetes also had signiﬁcantly lower HRQoL outcomes than those without 
diabetes (N = 43,326) (p < 0.001). CONCLUSIONS: In summary, macrovascular 
comorbidities signiﬁcantly decrease HRQoL in patients with diabetes.
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OBJECTIVES: This study was to compare health-related quality of life of patients 
with hypertension to people without hypertension. METHODS: Using the 2007 
NHANES of Korea, EuroQol (EQ-5D) was used to estimate a relation between quality 
of life and hypertension. In the analysis, adults (age ≥19 years old) at the time of the 
survey were included. EQ-5D as well as each 5 category such as mobility, self-care, 
usual activity, pain/discomfort and anxiety/depression were considered for the analy-
sis. For the estimation in EQ-5D, a generalized linear model with a logit link and the 
binomial family was used because EQ-5D was a proportion variable and had high 
negative skewness. In each speciﬁc category, there were 3 categories indicating good 
(1) to worse (3). Thus, ordered logit regressions were used for the analyses. In all 
analyses, age, gender, types of insurance, income, years of education and comorbid 
conditions were included. Survey weights were incorporated in the analyses to consider 
the survey design. RESULTS: A total of 2767 subjects was available. Among those, 
518 (18.7%) subjects had a hypertension based on self-report on whether they had 
hypertension or not. Mean (SD) in quality-of-life of patients with hypertension was 
0.84 (0.19), while mean (SD) of patients without hypertension was 0.93 (0.12). 
Among patients with hypertension, 51.7% were elderly (age >= 65 years) and 59.5% 
were female. Among patients without hypertension, 16.6% were elderly and 57.1% 
were female. Patients with hypertension as compare to people without hypertension 
were lower in quality of life by −0.20 (p-value: 0.038) after controlling other factors. 
Patients with hypertension were worsen in mobility and usual activity, but self-care, 
pain/discomfort and anxiety/depression had no difference from people without hyper-
tension. CONCLUSIONS: Patients with hypertension as compared to people without 
hypertension were lower in quality of life mostly due to difﬁculties in mobility and 
usual activity.
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OBJECTIVES: To characterize ACS-PCI patients including the index hospitalization 
charges and length-of-stay (LOS) in a US health beneﬁt plan. METHODS: The data 
source was Invision from i3, a division of UnitedHealth. ACS diagnoses were from 
ICD-9 codes 410.xx or 411.1. PCI procedure codes were 00.66, 36.0X, 92973, 92975, 
92978 −92982, 92984, 92995/6, and G0290/1. The deﬁnition of ACS-PCI was PCI 
within 30 days of an ACS diagnosis. The diagnosis related group (DRG) codes (555, 
556, 557, 558) and corresponding descriptions are from Version 23 and 24. Charges 
are in 2006 dollars. Continuous enrollment was required during the year 2006 and a 
minimum of 1 year before the index PCI. Patients with a history of transient ischemic 
attack or stroke were excluded. A clopidogrel claim was required within 60 days after 
hospitalization. RESULTS: Of the 6687 patients who had ACS-PCI and met the other 
inclusion criteria, 5174 (77.4%) were male, 5587 (83.6%) were under 65 years of 
age, and 1777 (26.6%) had a diabetes diagnosis. Drug-eluting stents (DES, n = 5541, 
82.9%) were frequently used. The 3249 patients with DRG557, DES with a major 
cardiovascular diagnosis (CVDx), had a mean length of stay (LOS) of 2.9 days and 
mean charges of $54,271. The 2292 patients with DRG558, DES without major 
CVDx, had a mean LOS of 1.7 days and mean charges of $44,230. The corresponding 
cohorts receiving bare metal stents (BMS) with (DRG555, n = 602) and without 
(DRG556, n = 187) major CVDx had mean LOS of 2.9 and 1.8 days with mean 
hospital charges of $46,106 and $34,109 respectively. CONCLUSIONS: For ACS 
patients who underwent PCI, the mean charge was approximately $10,000 higher and 
the mean LOS was 1 day longer for the cohort with major CVDx, as per the DRG 
deﬁnition, compared to the cohort without major CVDx.
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OBJECTIVES: Describe the management of ischemic stroke patients in acute phase 
and its impact on long-term stroke evolution in the USA. METHODS: Medline was 
searched from 1999 to date and ISPOR Digest was screened to identify stroke cohorts 
and registries containing data for the last ten years in the USA. A ranking process was 
implemented to identify and select the relevant references. RESULTS: A total of 461 
references were retrieved. The selection process led to the identiﬁcation of 78 publica-
tions (42 cohorts, 9 registries and 5 database studies) of which 41 focused on ischemic 
stroke only. Sixty-nine percent of the studies were hospital-based and 31% popula-
tion-based. The studies aimed to characterise determinants that impact acute phase 
management and outcomes, in particular demographic and clinical factors. Hospital 
settings and associated care facilities were studied in order to improve disease manage-
ment by identifying speciﬁc barriers to the administration of the only available throm-
bolytic treatment (recombinant tissue-type plasminogen activator, rt PA) in acute 
phase. Of these studies, many were not applicable to all ischemic stroke patients. 
Studies documenting the use of rt-PA showed that: less than 25% of patients arrived 
within 3 hours (i.e. time eligibility criteria for therapy) and 38.3% to 48.2% of them 
were excluded because of medical contraindications. Consequently, 10.9% to 14% of 
ischemic patients should have been given rt PA, but in natural settings, only 3.2% 
actually received it. In addition, long-term evolution of ischemic patients (mortality, 
stroke recurrence and cardiac events) was documented in several studies, but the evolu-
tion of disability after more than 3-months was not assessed. CONCLUSIONS: As 
shown above, general information about management of ischemic stroke in acute 
phase is lacking. New cohort or registry studies aiming to better describe patterns of 
ischemic stroke care that inﬂuence short and long-term clinical and associated eco-
nomic outcomes need to be developed.
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OBJECTIVES: The impact of Medicare’s Part D coverage gap (donut hole) on drug 
utilization was examined among patients with hypertension and/or hyperlipidemia, 
comparing treatment for asymptomatic (hypercholesterolemia and hypertension) and 
symptomatic (GI, depression, and pain) conditions. METHODS: The study sample 
consisted of patients from the 5% Medicare (A, B, and D) ﬁles with a diagnosis of 
hypertension and/or hyperlipidemia in 2005 and full-year (2006) fee-for-service, Medi-
care Part D and low-income subsidy (LIS) or non-LIS eligibility. Study outcomes 
included any drug use, adherence (percent days covered (PDC) ≥0.8), and discontinu-
ation (≥30-day continuous gap). The study employed a quasi-experimental design 
using a pre- (prior to donut hole) and post- (during donut hole) periods comparing 
three patient groups (non-LIS: without coverage, generic only coverage, and brand /
generic coverage during the gap) with a contemporaneous control group (LIS: no 
coverage gap). A difference-in-difference approach was used with multiple regressions 
controlling for demographic characteristics, Medicare entitlement status, area-level 
information, and clinical risk. RESULTS: The donut hole was associated with statisti-
cally signiﬁcant decreases in any drug use and PDC adherence, along with an increase 
in the likelihood of a discontinuation for both lipid lowering and antihypertensive 
drugs. The magnitude of impact was largest among patients without donut-hole drug 
coverage: 1.1% to 4.1% drop in probability of drug use; 4.4% to 12.1% decrease in 
adherence; and 4.5% to 12.5% increase in discontinuations (p < 0.01 for all). Impact 
was smallest among patients with both generic/brand drug coverage relative to the 
LIS controls. The donut hole had no impact on probability of using symptomatic drugs 
(anti-ulcer agents, antidepressants, and pain-killers). CONCLUSIONS: The donut 
hole was associated with statistically signiﬁcant but modest drops in the use of drugs 
for asymptomatic conditions, but had no impact on drugs for symptomatic conditions. 
Patients with no coverage during the donut hole experienced the largest impacts.
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BENEFICIARIES WITH HYPERTENSION
Shoemaker JS
University of Maryland Baltimore, Baltimore, MD, USA
OBJECTIVES: To assess the effect of Medicare Part D enrollment on changes in 
antihypertensive drug utilization for a nationally-representative sample of Medicare 
beneﬁciaries without prior prescription coverage. Part D enrollees have characteristics 
associated with above average drug use. To date, no nationally-representative studies 
have evaluated the impact of Part D on drug utilization controlling for these selection 
effects. Panel data methods address these biases in studying treatment for a chronic 
condition for which drug therapy can promote long term beneﬁts. METHODS: Lon-
gitudinal Medicare Current Beneﬁciary Survey (MCBS) data from the year before and 
after implementation of Part D. Unit of observation is the person-trimester, deﬁned 
as the interval between subsequent MCBS survey dates. Primary sample of beneﬁcia-
ries reporting a diagnosis of hypertension without drug coverage in 2005 and com-
pleted all 6 survey rounds in 2005 and 2006 (N = 3039 person trimesters). Secondary 
control sample of beneﬁciaries continuously enrolled in employer-sponsored insurance 
(ESI) as a sensitivity analysis (N = 5,608 person trimesters). Fixed effects and differ-
ence-in-difference (DID) multivariate methods compare changes in drug ﬁlls over six 
4-month periods for beneﬁciaries who enrolled in Part D and those who did not. 
RESULTS: A total of 67% of the primary sample enrolled in Part D. Descriptive trend 
analysis shows a monotonic increase in mean antihypertensive ﬁlls by trimester 
ranging from 4.0 to 7.1 for Part D enrollees, compared to a range from 2.7 to 4.4 for 
non-enrollees. In adjusted DID comparisons, Part D enrollees experienced 1.79 addi-
tional antihypertensive ﬁlls per trimester relative to non-enrollees (p < 0.05). Fixed 
effects methods suggest that Part D enrollees ﬁlled an additional 1.08 prescriptions 
per trimester (p < 0.05). Sensitivity analysis show comparable results. CONCLU-
SIONS: Enrollment in Part D increased drug utilization for a class of drugs known to 
